Analyst firms · J.P. Morgan · RMD
J.P. Morgan RMD price target and rating history
ResMed Inc. (RMD) · Health Care
J.P. Morgan rates ResMed Inc. (RMD) Overweight with a $170 price target, as of its latest action on Oct 9, 2023. It has published 6 rating actions on RMD since July 2021, including 4 upgrades and 2 downgrades. Across 5 firms with a RMD price target in the last 12 months, the median target is $235.
- Current rating
- Overweight
- Price target
- $170
- Median target, all firms
- $235
- Actions on RMD
- 6
J.P. Morgan price target on RMD
Every J.P. Morgan rating on RMD
- Oct 9, 2023
- Jan 17, 2023
- Aug 12, 2022
- Jan 24, 2022
- Jan 24, 2022
- Jul 26, 2021
How other firms rate RMD
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Canaccord Genuity | Hold | Nov 2, 2026 | |
| RBC Capital Markets | Outperform | $262 | Sep 15, 2026 |
| Rothschild & Co Redburn | Neutral | $230 | Aug 19, 2026 |
| Citigroup | Neutral | $235 | Jul 13, 2026 |
| Morgan Stanley | Equal-Weight | $230 | Jun 17, 2026 |
| Robert W. Baird | Neutral | $275 | Dec 16, 2025 |
Questions about J.P. Morgan and RMD
- What is J.P. Morgan's price target for RMD?
- J.P. Morgan's latest stated price target for ResMed Inc. (RMD) is $170, from its action on Oct 9, 2023.
- What is J.P. Morgan's rating on RMD?
- J.P. Morgan rates RMD Overweight, a bullish rating, as of Oct 9, 2023.
- When did J.P. Morgan last change its view on RMD?
- On Oct 9, 2023, J.P. Morgan upgrades to Overweight from Neutral, price target $210 to $170.
- How does J.P. Morgan's RMD target compare with other analysts?
- Across 5 firms with a RMD price target in the last 12 months, the median target is $235.
More RMD rating histories
- RBC Capital Markets13
- Citigroup8
- Morgan Stanley4
- Robert W. Baird4
- CLSA5
- Wolfe Research3
- Needham3
- BofA Securities3
All J.P. Morgan ratingsRMD news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.